

Journal of International Medical Research 2018, Vol. 46(2) 654-662 © The Author(s) 2017 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/0300060517716502 journals.sagepub.com/home/imr



# Efficacy of ondansetron for spinal anesthesia during cesarean section: a metaanalysis of randomized trials

# Chengmao Zhou<sup>1,</sup>\*, Yu Zhu<sup>1,</sup>\*, Zeqing Bao<sup>1,</sup>\*, Xianxue Wang<sup>2,\*</sup> and Qili Liu<sup>1</sup>

## Abstract

**Objective:** To investigate the efficacy and safety of ondansetron during cesarean section under spinal anesthesia.

Methods: We sought randomized controlled trials (RCTs) on ondansetron during spinal anesthesia for cesarean section in The Cochrane Library, PubMed, MEDLINE, and Web of Science from their inception to September 2016.

Results: Altogether, 21 RCTs were included in this study. Meta-analysis showed that the ondansetron group had a lower incidence of nausea/vomiting and bradycardia than the placebo group during cesarean section under spinal anesthesia [relative risk (RR) = 0.43, 95% confidence interval (CI) (0.36, 0.51) and RR = 0.45, 95% CI (0.26, 0.80), respectively]. There were no significant differences in the incidences of pruritus, hypotension, or shivering during cesarean section under spinal anesthesia [RR = 0.92, 95% CI (0.83, 1.02); RR = 0.72 (0.50, 1.06), 95% CI (0.50, 1.06); and RR = 0.89, 95% CI (0.71, 1.11), respectively].

**Conclusion:** Ondansetron effectively reduces the incidences of nausea/vomiting and bradycardia under spinal anesthesia during cesarean section.

## **Keywords**

Ondansetron, spinal anesthesia, cesarean section, meta-analysis, RCT, shivering, nausea/vomiting

Date received: 4 February 2017; accepted: 31 May 2017

# Introduction

The focus of obstetric anesthesia is to ensure the safety of mother and child. Therefore, it is essential to select the anesthesia and its administration carefully. Spinal anesthesia, because it is a simple medication that has little impact on the fetus, has become a preferred choice for cesarean section.

<sup>1</sup>Zhaoqing Medical College, Zhaoqing, China <sup>2</sup>Department of Anesthesiology, The First People's Hospital of Changde, Changde, China

\*These authors are equal contributors to this article.

**Corresponding author:** 

Qili Liu, Zhaoqing Medical College, No. 6 Xijiangnan Road, Zhaoqing 526020, China. Email: liugili187@163.com

Creative Commons CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial  $(\mathbf{i})$ 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and BY NC distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us. sagepub.com/en-us/nam/open-access-at-sage).

The Apgar score of the fetus under spinal anesthesia for cesarean section was higher than that under general anesthesia.<sup>1,2</sup> Although spinal anesthesia is ideal for cesarean section, it also causes adverse reactions. Spinal anesthesia can lead to severe bradycardia or hypotension in puerperae who display unstable hemodynamics.<sup>3</sup> Yeh et al.<sup>4</sup> found that, because of the special physiological characteristics of obstetrics, the postoperative incidence of pruritus may be as high as 85% in patients who have epidural analgesia with morphine after cesarean section. In addition, according to Teresa and Cartoon,<sup>5</sup> the incidence of shivering during cesarean section is as high as 57%. Patientcontrolled intravenous analgesia is commonly used after cesarean section. As most analgesic drugs are opioids, however, they often trigger nausea, vomiting, and other adverse puerperal reactions after cesarean section.

Currently, ondansetron is widely used during cesarean section, and numerous related high-quality studies have been published. To date, however, there has been no metaanalysis of ondansetron used during cesarean section under spinal anesthesia. We therefore conducted a meta-analysis to investigate the efficacy and safety of ondansetron during cesarean section under spinal anesthesia.

# Materials and methods

## Inclusion criteria

- Study design: randomized controlled trials (RCTs), regardless of whether allocation concealment and blinding were used.
  - Study subjects: patients given ondansetron during cesarean section under spinal anesthesia.
  - Interventions: (1) ondansetron administration (experimental group); (2) administration of a placebo (control group).

• Outcome measures: Main: incidence of nausea/vomiting. Secondary: incidence of pruritus, bradycardia, shivering, hypotension.

# Exclusion criterion

• Literature had no specific data or full text.

# Search strategy

The Cochrane Library, PubMed, MEDLINE, and Web of Science were searched for RCTs studying ondansetron given under spinal anesthesia for cesarean section from the database inception to September 2016. English search terms included "randomized controlled trial," "controlled clinical trial," "cesarean section," "ondansetron," "epidural," "spinal," among others. For example, a specific search strategy in PubMed is described in Box 1.

#1 epidural
#2 subarachnoid space
#3 spinal
#4 ondansetron
#5 cesarean section
#6 randomized controlled trial
#7 #1 OR #2 OR #3
#8 #4 AND #7 AND #5 AND #6

Literature screening, data extraction, and quality evaluation. Two reviewers independently selected the literature, extracted the data, and assessed the quality according to the inclusion and exclusion criteria. When there was a disagreement, it was resolved by further discussion. The contents of the data extraction included the title, author, publication year, study objects and characteristics, sample size, interventions, outcome measures and measurement results, quality evaluation, and other related contents. Jadad scores were performed in terms of the randomization method employed and if there was allocation concealment. Also considered were the presence of blinding, withdrawal, or dropouts.

## Statistical analysis

A meta-analysis was performed via using RevMan 5.2 provided by the Cochrane Collaboration. Enumeration data were presented as relative risk (RR) or odds ratio (OR) with a 95% confidence interval (CI). Measurement data were expressed as the mean difference (MD) with a 95% CI. The heterogeneity among included studies was tested by the  $\chi^2$  test. If homogeneity was found (P > 0.10,  $I^2 < 50\%$ ), a fixed-effects model was employed for the meta-analysis. If P < 0.1 and  $I^2 \ge 50\%$ , we further analyzed the source of heterogeneity. A randomeffects model for the meta-analysis was used in the absence of significant clinical heterogeneity, and a subgroup analysis or descriptive analysis was used in the presence of significant clinical heterogeneity.

## Results

#### Literature search results

Initially, 728 related articles were detected, with 21 RCTs finally enrolled after stepby-step screening.<sup>6-26</sup> The literature screening process and results are shown in Figure 1.

For the basic characteristics of the included studies see Table 1. The methodological quality assessment of the included studies is also shown in Table 1 (Jadad score).

### Meta-analysis results

Maternal side effects, including hypotension, nausea/vomiting, and shivering, were compared between the ondansetron and placebo groups. There were no significant differences in the incidences of pruritus, hypotension, or shivering during cesarean



Figure 1. Flow diagram for the study. RCTs, randomized controlled trials.

Study	Country	Head count (E/P)	Ondansetron treatment target <sup>a</sup>	Jadad score
Abouleish 1999	USA	74 (36/38)	2,3	6
Browning 2013	Australia	116 (56/60)	4	5
Charuluxananan 2003	Thailand	120 (60/60)	1,2	5
El-Deeb 2011	Egypt	300 (150/150)	2	5
Fattahi 2015	Iran	212 (106/106)	2	6
Koju 2015	Nepal	50 (25/25)	2,4	5
Marciniak 2015	Poland	70 (36/34)	1,2,5	6
Moustafa 2016	Egypt	60 (24/28)	1,2,4	6
Ortiz-Gómez 2014	Spain	64 (32/32)	1,2	5
Pan 1996	Virginia	32 (16/16)	2	5
Pan 2001	Canada	105 (54/51)	2	5
Rashad 2013	Egypt	40 (20/20)	2,4,5	5
Sahoo 2012	India	52 (26/26)	2,4	5
Sarvela 2006	Finland	59 (30/29)	1,2	6
Siddik-Sayyid 2007	Lebanon	87 (42/45)	1,2	5
Terkawi 2015	USA	86 (44/42)	1,2,3	5
Trabelsi 2015	Tunisia	80 (40/40)	2,3,5	6
Wang M 2014	China	60 (30/30)	2,3,5	5
Wang Q 2014	China	65 (33/32)	2,3,5	5
Yazigi 2002	Lebanon	100 (50/50)	1,2	5
Yeh 2000	Taiwan	40 (20/20)	I	5

Table 1. Characteristics and Jadad scores of the included studies in the meta-analysis.

E/P: intervention group (ondansetron)/placebo (saline) group

<sup>a</sup>I, Pruritus; 2, nausea/vomiting; 3, hypotension; 4, shivering; 5, bradycardia

	Ondanse		place			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% CI
Charuluxananan 2003	53	60	56	60	28.5%	0.95 [0.84, 1.06]	
Marciniak 2015	9	36	9	34	1.7%	0.94 [0.43, 2.09]	
Moustafa 2016	24	30	28	30	16.5%	0.86 [0.70, 1.05]	-
Ortiz-Gomez 2014	1	32	1	32	0.1%	1.00 [0.07, 15.30]	
Sarvela 2006	20	30	22	29	8.4%	0.88 [0.63, 1.22]	-
Siddik-Sayyid 2007	35	42	39	45	19.3%	0.96 [0.81, 1.15]	+
Terkawi 2015	28	44	23	42	7.3%	1.16 [0.82, 1.66]	+-
Yaigi 2002	38	50	41	50	16.5%	0.93 [0.76, 1.14]	+
Yeh 2000	5	20	17	20	1.7%	0.29 [0.13, 0.64]	
Total (95% CI)		344		342	100.0%	0.92 [0.83, 1.02]	•
Total events	213		236				
Heterogeneity: Tau <sup>2</sup> = 0.	01; Chi <sup>2</sup> = 1	1.36, d	f= 8 (P =	0.18);	<b>*</b> = 30%		
Test for overall effect: Z =	= 1.56 (P =	0.12)					ondansetron placebo



section under spinal anesthesia [RR = 0.92, 95% CI ([0.83, 1.02); RR = 0.72, 95% CI (0.50, 1.06); and RR = 0.89, 95% CI (0.71, 1.11), respectively] (Figure 2, Figure 3).

*Nausea/vomiting.* A total of 18 RCTs including 1630 patients were enrolled in this study. The incidences of nausea/vomiting caused by spinal anesthesia during cesarean section

AL	Ondanse		placel			Risk Ratio	Risk Ratio
Study or Subgroup	Events					M-H, Random, 95%	
Abouleish 1999	26	36	25	38	23.7%	1.10 [0.81, 1.4	
Terkawi 2015	26	42	25	41	22.8%	1.02 [0.72, 1.4	
Trabelsi 2015	15	40	31	40	20.5%	0.48 [0.31, 0.7	
Wang M 2014	12	30	18	30	18.2%	0.67 [0.39, 1.1	
Wang Q 2014	8	33	18	32	14.8%	0.43 [0.22, 0.8	:5]
Total (95% CI)		181		181	100.0%	0.72 [0.50, 1.0	6] 🔶
Total events	87		117				
Heterogeneity: Tau <sup>2</sup> =	0.14; Chi2	= 15.78	df = 4 (F	P = 0.00	03); I <sup>2</sup> = 7	5%	0.01 0.1 1 10 100
Test for overall effect:	Z = 1.66 (F	P = 0.10)	)				ondansetron placebo
(b)	Ondans	etron	place	bo		<b>Risk Ratio</b>	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Browing 2013	41	56					
Ortiz-Gomez 2014	3	30	3	30	5.6%		
Rashad 2013	2	20	5	20	9.4%		
Total (95% CI)		106		110	100.0%	0.89 [0.71, 1.11]	•
Total events	46		55				
Heterogeneity: Chi <sup>2</sup> =	- 1 22 df-	2/P = 0	621-12-	0%			
Heterogeneity. Chir -	= 1.32, ui =	2(F = 0	.52), 1 -				0.04 0.4 4 40 400
Test for overall effect							0.01 0.1 1 10 100 ondansetron placebo
	t: Z = 1.04 (	P = 0.30	))			Risk Ratio	ondansetron placebo
Test for overall effect (C)		P = 0.30	)) placel	bo	Weight	Risk Ratio M-H, Fixed, 95% Cl	
Test for overall effect	t: Z = 1.04 ( Ondanse	P = 0.30	)) placel Events	bo	Weight 6.2%	M-H, Fixed, 95% Cl	ondansetron placebo Risk Ratio
Test for overall effect (C) Study or Subgroup	t Z = 1.04 ( Ondanse Events	P = 0.30 tron Total	)) placel <u>Events</u> 2	bo Total		M-H, Fixed, 95% Cl 0.47 [0.04, 4.97]	ondansetron placebo Risk Ratio
Test for overall effect (C) <u>Study or Subgroup</u> Marciniak 2015	t: Z = 1.04 () Ondanse <u>Events</u> 1	P = 0.30 tron <u>Total</u> 36	)) placel Events	bo <u>Total</u> 34	6.2%	M-H, Fixed, 95% Cl 0.47 [0.04, 4.97] 0.20 [0.01, 3.92]	ondansetron placebo Risk Ratio
Test for overall effect (C) <u>Study or Subgroup</u> Marciniak 2015 Rashad 2013	t Z = 1.04 ( Ondanse <u>Events</u> 1 0	P = 0.30 tron <u>Total</u> 36 20	)) placel <u>Events</u> 2 2	bo <u>Total</u> 34 20	6.2% 7.6%	M-H, Fixed, 95% Cl 0.47 [0.04, 4.97] 0.20 [0.01, 3.92] 0.20 [0.01, 3.97]	ondansetron placebo Risk Ratio
Test for overall effect (C) <u>Study or Subgroup</u> Marciniak 2015 Rashad 2013 Sahoo 2012	t: Z = 1.04 ( Ondanse <u>Events</u> 1 0 0	P = 0.30 tron <u>Total</u> 36 20 26	placel Events 2 2 2	500 Total 34 20 26	6.2% 7.6% 7.6%	M-H, Fixed, 95% Cl 0.47 [0.04, 4.97] 0.20 [0.01, 3.92]	ondansetron placebo Risk Ratio
Test for overall effect (c) <u>Study or Subgroup</u> Marciniak 2015 Rashad 2013 Sahoo 2012 Terkawi 2015	t: Z = 1.04 ( Ondanse <u>Events</u> 1 0 0 6	P = 0.30 tron <u>Total</u> 36 20 26 41	placel Events 2 2 2 6	500 Total 34 20 26 41	6.2% 7.6% 7.6% 18.1%	M-H, Fixed, 95% Cl 0.47 [0.04, 4.97] 0.20 [0.01, 3.92] 0.20 [0.01, 3.97] 1.00 [0.35, 2.84]	ondansetron placebo Risk Ratio
Test for overall effect (c) <u>Study or Subgroup</u> Marciniak 2015 Rashad 2013 Sahoo 2012 Terkawi 2015 Trabelsi 2015	t: Z = 1.04 () Ondanse Events 1 0 0 6 6	P = 0.30 tron <u>Total</u> 36 20 26 41 40	placel Events 2 2 2 6 15	bo <u>Total</u> 34 20 26 41 40	6.2% 7.6% 7.6% 18.1% 45.3%	M-H, Fixed, 95% Cl 0.47 [0.04, 4.97] 0.20 [0.01, 3.92] 0.20 [0.01, 3.97] 1.00 [0.35, 2.84] 0.40 [0.17, 0.93]	ondansetron placebo Risk Ratio
Test for overall effect (C) <u>Study or Subgroup</u> Marciniak 2015 Rashad 2013 Sahoo 2012 Terkawi 2015 Trabelsi 2015 Wang M 2014	t: Z = 1.04 () Ondanse Events 1 0 6 6 6 0	P = 0.30 tron <u>Total</u> 36 20 26 41 40 30	)) placel Events 2 2 2 6 15 2	bo <u>Total</u> 34 20 26 41 40 30 32	6.2% 7.6% 7.6% 18.1% 45.3% 7.6%	M-H, Fixed, 95% CI 0.47 [0.04, 4.97] 0.20 [0.01, 3.92] 0.20 [0.01, 3.97] 1.00 [0.35, 2.84] 0.40 [0.17, 0.93] 0.20 [0.01, 4.00]	ondansetron placebo Risk Ratio
Test for overall effect (c) Marciniak 2015 Rashad 2013 Sahoo 2012 Terkawi 2015 Trabelsi 2015 Wang M 2014 Wang Q 2014	t: Z = 1.04 () Ondanse Events 1 0 6 6 6 0	P = 0.30 tron <u>Total</u> 36 20 26 41 40 30 33	)) placel Events 2 2 2 6 15 2	bo <u>Total</u> 34 20 26 41 40 30 32	6.2% 7.6% 7.6% 18.1% 45.3% 7.6% 7.7%	M-H, Fixed, 95% Cl 0.47 [0.04, 4.97] 0.20 [0.01, 3.92] 0.20 [0.01, 3.97] 1.00 [0.35, 2.84] 0.40 [0.17, 0.93] 0.20 [0.01, 4.00] 0.19 [0.01, 3.89]	ondansetron placebo Risk Ratio
Test for overall effect (c) <u>Study or Subgroup</u> Marciniak 2015 Rashad 2013 Sahoo 2012 Terkawi 2015 Trabelsi 2015 Wang M 2014 Wang Q 2014 Total (95% CI)	t: Z = 1.04 () Ondanse Events 1 0 6 6 6 0 0 13	P = 0.30 tron Total 36 20 26 41 40 30 33 226	)) placel <u>Events</u> 2 2 2 6 15 2 2 2 31	bo <u>Total</u> 34 20 26 41 40 30 32 223	6.2% 7.6% 7.6% 18.1% 45.3% 7.6% 7.7%	M-H, Fixed, 95% Cl 0.47 [0.04, 4.97] 0.20 [0.01, 3.92] 0.20 [0.01, 3.97] 1.00 [0.35, 2.84] 0.40 [0.17, 0.93] 0.20 [0.01, 4.00] 0.19 [0.01, 3.89]	ondansetron placebo Risk Ratio

Figure 3. Studies reporting the incidence of (a) hypotension, (b) shivering, and (c) bradycardia with ondansetron administration.

were reported. The meta-analysis results of the fixed-effects model showed that the incidence of nausea/vomiting was significantly lower in the ondansetron group than in the placebo group [RR = 0.43, 95% CI (0.36, 0.51), P < 0.00001] (Figure 4).

*Bradycardia*. A total of 7 RCTs, with 449 people, were included in the study. Bradycardia triggered by spinal anesthesia during cesarean section was reported. The meta-analysis results of the fixed-effects model showed that the incidence of bradycardia in the ondansetron group was

statistically significantly lower than that in the placebo group [RR = 0.45, 95% CI (0.26, 0.80), P = 0.006] (Figure 4(c)).

## Discussion

We conducted subgroup analyses on the 21 included studies according to the outcome indicators of the control group. The results showed that the ondansetron group experienced significantly lower incidences of bradycardia and nausea/vomiting than the placebo group under spinal anesthesia during cesarean section. The two groups,

	Ondanse	etron	place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
Abouleish 1999	15	36	21	38	6.4%	0.75 [0.47, 1.22]	-+
Charuluxananan 2003	11	60	20	60	6.3%	0.55 [0.29, 1.05]	
El-Deeb 2011	33	150	69	150	21.6%	0.48 [0.34, 0.68]	
Fattahi 2015	6	106	39	106	12.2%	0.15 [0.07, 0.35]	
Koju 2015	2	25	14	25	4.4%	0.14 [0.04, 0.56]	
Marciniak 2015	4	36	4	34	1.3%	0.94 [0.26, 3.48]	
Moustafa 2016	3	30	3	30	0.9%	1.00 [0.22, 4.56]	
Ortiz-Gomez 2014	2	32	7	32	2.2%	0.29 [0.06, 1.27]	
Pan 1996	5	16	11	16	3.4%	0.45 [0.20, 1.01]	
Pan 2001	14	54	36	51	11.6%	0.37 [0.23, 0.60]	
Rashad 2013	1	20	8	20	2.5%	0.13 [0.02, 0.91]	
Sahoo 2012	1	26	7	26	2.2%	0.14 [0.02, 1.08]	
Sarvela 2006	6	30	6	29	1.9%	0.97 [0.35, 2.65]	
Siddik-Sayyid 2007	10	42	14	45	4.2%	0.77 [0.38, 1.53]	
Trabelsi 2015	9	40	15	40	4.7%	0.60 [0.30, 1.21]	
Wang M 2014	3	30	10	30	3.1%	0.30 [0.09, 0.98]	
Wang Q 2014	2	33	11	32	3.5%	0.18 [0.04, 0.73]	
Yaigi 2002	9	50	24	50	7.5%	0.38 [0.19, 0.72]	
Total (95% CI)		816		814	100.0%	0.43 [0.36, 0.51]	•
Total events	136		319				
Heterogeneity: Chi <sup>2</sup> = 28	.87, df = 17	(P=0.	$(04);  ^2 = 4$	1%			0.01 0.1 1 10 100
Test for overall effect: Z =	= 9.70 (P <	0.0000	1)				ondansetron placebo

Figure 4. Studies reporting nausea and vomiting with ondansetron administration.

however, differed little in their incidences of pruritus, hypotension, or shivering.

Ondansetron is a potent, highly selective serotonin (5-HT3) receptor antagonist. It can prevent the combination of 5-HT released by activated platelets with 5-HT3 receptors in the vagal nerve endings of the left ventricle, attenuate Bezold–Jarisch reflexes produced by left ventricular mechanoreceptors stimulated by 5-HT, inhibit further expansion of peripheral blood vessels, and increase venous return, thereby reducing the incidence of hypotension.<sup>27,28</sup>

Owczuk et al.<sup>29</sup> observed that intravenously injecting 8 mg ondansetron 5 min before spinal anesthesia can curb the reduction of systolic blood pressure without affecting the diastolic blood pressure or heart rate. Sahoo et al.<sup>14</sup> reported that intravenous injection of 8 mg ondansetron 5 min before spinal anesthesia can significantly reduce the incidences of hypotension, nausea, and vomiting in puerperae undergoing spinal anesthesia and reduce the use of vasoconstrictor drugs. Ondansetron is structurally similar to 5-HT3 and has a high selectivity of dense region in the 5-HT3 receptor. It can block vomiting reflexes caused by the 5-HT3 receptor-induced vagal stimulation and inhibit 5-HT release in the fourth ventricle caused by vagal excitement, effectively controlling vomiting. Several studies have demonstrated that ondansetron can significantly reduce the incidence of postoperative nausea/vomiting.<sup>30</sup>

Giving ondansetron to prevent pruritus and shivering is still debatable. A possible mechanism for initiating pruritus is opioid spread via cerebrospinal fluid to the head, where it acts on the medulla oblongata and spinal L receptors or 5- HT3 receptors. Ondansetron, a selective 5-HT3 receptor antagonist, is commonly used to prevent or treat nausea/vomiting after surgery and chemotherapy. Several clinical studies have confirmed<sup>8,31</sup> that it can effectively control pruritus due to intrathecal injection of morphine. In the present study, ondansetron did not effectively prevent skin pruritus caused by intrathecal injection of sufentanil, possibly because the ondansetron had not yet reached the location to make the difference. In addition to medulla oblongata and 5-HT3 receptors, opioids have many other ways to produce pruritus. Ondansetron can effectively prevent morphine- or fentanylinduced skin pruritus. Yazigi et al.<sup>32</sup> believed that ondansetron's antagonism cannot be used effectively as sufentanil has higher fat solubility than the former two drugs, thus acting on the medulla oblongata and spinal cord more rapidly.

Shivering is a common complication of anesthesia. Currently, the mechanism of postoperative shivering is not entirely clear. It may relate to dysfunctional temperature regulation, or it may be associated with the recovery sequence of the nerve center after anesthesia. One study showed that 5-HT secreted by the hypothalamus plays an important role in thermoregulation.<sup>33</sup> In animal models, intravenous injection of 5-HT into mice can induce hemangiectasis, causing shivering,<sup>34</sup> suggesting that the 5-HT system plays an important role in controlling postoperative shivering. Studies have shown that 5-HT3 antagonists play a part in preventing postoperative shivering, and its mechanism may be associated with inhibition of 5-HT in the preoptic anterior hypothalamus.35

The adverse reactions of ondansetron often present as neurological symptoms (e.g., headache, dizziness) or digestive symptoms (e.g., abdominal discomfort, abnormally elevated alanine aminotransferase), but the overall incidences are relatively low.

There are some limitations of this systematic review. (1) The included studies differ in regard to the patient's position, the anesthesia puncture points, measurement indicators, and use of drugs—each of which could affect the conclusions of this study. (2) The heterogeneity of the included studies is distinct, which may influence the reliability of the meta-analysis. (3) RCTs included in some subgroup analyses were not enough. (4) Some RCTs did not give enough information to judge the scientific rationality of the trial, and there was a possibility of implementation biases and measurement biases. Meanwhile, as we only covered the published literature, the search strategy and publication bias could also affect the results of this study.

In summary, ondansetron can effectively reduce the incidences of nausea, vomiting, and bradycardia during spinal anesthesia for cesarean section, and its safety is relatively good. Because of the small sample size of this study, this conclusion remains to be confirmed by studies with a larger sample size and multi-center studies.

### Acknowledgements

The authors are grateful to You-Jing Luo, MD for her extensive support throughout the article development, which substantially improved the quality of the manuscript.

#### **Declaration of conflicting interest**

The authors declare that there is no conflict of interest.

#### Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

#### References

- Solangi SA, Siddiqui SM, Khashheli MS, et al. Comparison of the effects of general vs. spinal anesthesia on neonatal outcome. *Anaesth Intens Care* 2012; 16: 18–23.
- Kolatat T, Somboonnanonda A, Lertakyamanee J, et al. Effects of general and regional anesthesia on the neonate (a prospective, randomized trial). *J Med Assoc Th ailand* 1999; 82: 40–45.

- Lyons G. Saving mothers, lives: confidential enquiry into maternal and child health: 2003-5. *Int J Obstet Anesth* 2008; 17: 103.
- Yeh HM, Chen LK, Lin CJ, et al. Prophylactic intravenous ondansetron reduces the incidence of intrathecal morphine-induced pruritus in patients undergoing cesarean delivery. *Anesth Analg* 2000; 9: 172.
- Teresa VG and Cartoon RF. Shivering post epidural anesthesia different doses of intravenous clonine. *Can J Anesth* 2002; 49: 54.
- Abouleish EI, Rashid S, Haque S, et al. Ondansetron versus placebo for the control of nausea and vomiting during Caesarean section under spinal anaesthesia. *Anaesthesia* 1999; 54: 479–482.
- Browning RM, Fellingham WH, O'Loughlin EJ, et al. Prophylactic ondansetron does not prevent shivering or decrease shivering severity during cesarean delivery under combined spinal epidural anesthesia: a randomized trial. *Reg Anesth Pain Med* 2013; 38: 39–43.
- Charuluxananan S, Kyokong O, Somboonviboon W, et al. Nalbuphine versus ondansetron for prevention of intrathecal morphine-induced pruritus after cesarean delivery. *Anesth Analg* 2003; 96: 1789–1793.
- El-Deeb AM and Ahmady MS. Effect of acupuncture on nausea and/or vomiting during and after cesarean section in comparison with ondansetron. *J Anesth* 2011; 25: 698–703.
- Moustafa AA, Baaror AS and Abdelazim IA. Comparative study between nalbuphine and ondansetron in prevention of intrathecal morphine-induced pruritus in women undergoing cesarean section. *Anesth Essays Res* 2016; 10: 238–244.
- Ortiz-Gomez JR, Palacio-Abizanda FJ, Morillas-Ramirez F, et al. The effect of intravenous ondansetron on maternal haemodynamics during elective caesarean delivery under spinal anaesthesia: a doubleblind, randomised, placebo-controlled trial. *Int J Obstet Anesth* 2014; 23: 138–143.
- 12. Pan PH and Moore CH. Comparing the efficacy of prophylactic metoclopramide, ondansetron, and placebo in cesarean

section patients given epidural anesthesia. *J Clin Anesth* 2001; 13: 430–435.

- Pan PH and Moore CH. Intraoperative antiemetic efficacy of prophylactic ondansetron versus droperidol for cesarean section patients under epidural anesthesia. *Anesth Analg* 1996; 83: 982–986.
- Sahoo T, Sendasgupta C, Goswami A, et al. Reduction in spinal-induced hypotension with ondansetron in parturients undergoing caesarean section: a double-blind randomised, placebo-controlled study. *Int J Obstet Anesth* 2012; 21: 24–28.
- Sarvela PJ, Halonen PM, Soikkeli AI, et al. Ondansetron and tropisetron do not prevent intraspinal morphine- and fentanyl-induced pruritus in elective cesarean delivery. *Acta Anaesthesiol Scand* 2006; 50: 239–244.
- Siddik-Sayyid SM, Aouad MT, Taha SK, et al. Does ondansetron or granisetron prevent subarachnoid morphine-induced pruritus after cesarean delivery? *Anesth Analg* 2007; 104: 421–424.
- Terkawi AS, Tiouririne M, Mehta SH, et al. Ondansetron does not attenuate hemodynamic changes in patients undergoing elective cesarean delivery using subarachnoid anesthesia: a double-blind, placebocontrolled, randomized trial. *Reg Anesth Pain Med* 2015; 40: 344–348.
- Trabelsi W, Romdhani C, Elaskri H, et al. Effect of Ondansetron on the occurrence of hypotension and on neonatal parameters during spinal anesthesia for elective caesarean section: a prospective, randomized, controlled, double-blind study. *Anesthesiol Res Pract* 2015; 2015: 158061.
- Wang M, Zhuo L, Wang Q, et al. Efficacy of prophylactic intravenous ondansetron on the prevention of hypotension during cesarean delivery: a dose-dependent study. *Int J Clin Exp Med* 2014; 7: 5210–5216.
- Wang Q, Zhuo L, Shen MK, et al. Ondansetron preloading with crystalloid infusion reduces maternal hypotension during cesarean delivery. *Am J Perinatol* 2014; 31: 913–922.
- 21. Yazigi A, Chalhoub V, Madi-Jebara S, et al. Prophylactic ondansetron is effective in the treatment of nausea and vomiting but not on pruritus after cesarean delivery with

intrathecal sufentanil-morphine. J Clin Anesth 2002; 14: 183–186.

- Yeh HM, Chen LK, Lin CJ, et al. Prophylactic intravenous ondansetron reduces the incidence of intrathecal morphine-induced pruritus in patients undergoing cesarean delivery. *Anesth Analg* 2000; 91: 172–175.
- Fattahi Z, Hadavi SM and Sahmeddini MA. Effect of ondansetron on post-dural puncture headache (PDPH) in parturients undergoing cesarean section: a double-blind randomized placebo-controlled study. J Anesth 2015; 29: 702–707.
- Rashad MM and Farmawy MS. Effects of intravenous ondansetron and granisetron on hemodynamic changes and motor and sensory blockade induced by spinal anesthesia in parturients undergoing cesarean section. *Eg J Anaesth* 2013; 29: 369–374.
- 25. Marciniak A, Owczuk R, Wujtewicz M, et al. The influence of intravenous ondansetron on maternal blood haemodynamics after spinal anaesthesia for caesarean section: a doubleblind, placebo-controlled study. *Ginekol Polska* 2015; 86: 461–467.
- 26. Koju RB, Gurung BS and Dongol Y. Prophylactic administration of ondansetron in prevention of intrathecal morphineinduced pruritus and post-operative nausea and vomiting in patients undergoing caesarean section. *BMC Anesthesiol* 2015; 15: 15–18.
- Rashad MM and Farmawy MS. Effects of intravenous ondansetron and granisetron on hemodynamic changes and motor and sensory blockade induced by spinal anesthesia in parturients undergoing cesarean section. *Eg J Anaesth* 2013; 29: 369–374.

- 28. Martinek RM. Witnessed asystole during spinal anesthesia treated with atropine and ondansetron: a case report. *Can J Anaesth* 2004; 51: 226.
- Owczuk R, Wenski W, Polak-Krze minska A, et al. Ondansetron given intravenously attenuates arterial blood pressure drop due to spinal anesthesia: a double-blind, placebocontrolled study. *Reg Anesth Pain Med* 2008; 33: 332.
- Alghanem SM, Massad IM, Rashed EM, et al. Optimization of anesthesia antiemetic measures versus combination therapy usine dexamethasone or ondansetron for the prevention of postoperative nausea and vomiting. *Surg Endosc* 2010; 24: 353–358.
- Charuluxananan S, Somboonviboon W, Kyokong O, et al. Ondansetron for treatment of intrathecal morphine-induced pruritus after cesarean delivery. *RegAnesth PainMed* 2000; 25: 535–539.
- 32. Yazigi A, Chalhoub V, Madi-Jebara S, et al. Ondansetron for prevention of intrathecal opioids-induced pruritus, nausea and vomiting after cesarean delivery. *Anesth Analg* 2004; 98: 264.
- Hsieh MT, Chueh FY and Lin MT. Magnolol decreases body temperature by reducing 5-hydroxytryptamine release in the rat hypothalamus. *Clin Exp Pharmacol Physiol* 1998; 25: 813–817.
- Dawson NJ and Malcolm JL. Initiation and inhibition of shivering in the rat: interaction between peripheral and central factors. *Clin Exp Pharmacol Physiol* 1982; 9: 89–93.
- Alfonsi P. Postanaesthetic shivering epidemiology, pathophysiology and approaches to prevention and management. *Drugs* 2001; 61: 2193–2205.